Ultragenyx Pharmaceutical (RARE) Stock Statistics & Valuation Metrics

Ultragenyx Pharmaceutical has a market cap or net worth of $2.57B. The enterprise value is $2.48B.

Ultragenyx Pharmaceutical has 94,542,040 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ultragenyx Pharmaceutical’s return on equity (ROE) is -2.23 and return on invested capital (ROIC) is -45.55%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Ultragenyx Pharmaceutical had revenue of 560.23M and earned -569.18M in profits. Earnings per share was -6.29.

In the last 12 months, operating cash flow was -389.94M and capital expenditures -23.10M, giving a free cash flow of -413.04M billion.

Ultragenyx Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―

Ultragenyx Pharmaceutical upcoming earnings date is Jul 31, 2025, TBA (Confirmed).

Ultragenyx Pharmaceutical as a current ratio of 2.37, with Debt / Equity ratio of 26.53%

In the past 12 months, Ultragenyx Pharmaceutical has paid 1.60M in taxes.

Ultragenyx Pharmaceutical EV to EBITDA ratio is -7.84, with an EV/FCF ratio of -8.72.

Ultragenyx Pharmaceutical has $494.44M in cash and marketable securities with $38.27M in debt, giving a net cash position of -$456.17M billion.

Gross margin is 83.63%, with operating margin of -95.67%, and net profit margin of -101.60%.

The average price target for Ultragenyx Pharmaceutical is $82.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy